Dr. Lonial Discusses the Importance of Partnering With a Myeloma Center

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing transplant.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns guiding management strategies.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

The FDA approved brentuximab vedotin, lenalidomide, and rituximab for large B-cell lymphoma after 2 therapies in patients ineligible for transplant or chimeric antigen receptor T-cell therapy.

The FDA has accepted the resubmitted biologics license application for linvoseltamab to treat relapsed/refractory multiple myeloma in heavily pretreated adults.